Clinical Trials Related to Metastatic Colorectal Cancer

Related studies linked through entity extraction aliases.

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

Status: COMPLETED
Phase: PHASE2

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Status: COMPLETED
Phase: PHASE2

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Status: COMPLETED
Phase: PHASE1

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)

Status: UNKNOWN
Phase: N/A

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Status: COMPLETED
Phase: PHASE1

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Status: COMPLETED
Phase: PHASE3

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Status: UNKNOWN
Phase: PHASE2

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Status: WITHDRAWN
Phase: PHASE2

The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer

Status: UNKNOWN
Phase: PHASE2

Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients

Status: UNKNOWN
Phase: PHASE2

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Status: COMPLETED
Phase: PHASE3

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Status: COMPLETED
Phase: PHASE2

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Status: WITHDRAWN
Phase: PHASE1/PHASE2

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Status: TERMINATED
Phase: PHASE1

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

Status: COMPLETED
Phase: PHASE2

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Status: UNKNOWN
Phase: PHASE2

The CHOICE Registry

Status: TERMINATED
Phase: N/A

Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)

Status: UNKNOWN
Phase: NA